CN106536751A - 治疗抑郁症和重性抑郁障碍的方法 - Google Patents
治疗抑郁症和重性抑郁障碍的方法 Download PDFInfo
- Publication number
- CN106536751A CN106536751A CN201580023401.1A CN201580023401A CN106536751A CN 106536751 A CN106536751 A CN 106536751A CN 201580023401 A CN201580023401 A CN 201580023401A CN 106536751 A CN106536751 A CN 106536751A
- Authority
- CN
- China
- Prior art keywords
- variant
- cacna1c
- csmd1
- zscan4
- positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 135
- 208000024714 major depressive disease Diseases 0.000 title claims abstract description 82
- 101000785573 Homo sapiens Zinc finger and SCAN domain-containing protein 4 Proteins 0.000 claims abstract description 162
- 102100026569 Zinc finger and SCAN domain-containing protein 4 Human genes 0.000 claims abstract description 159
- 229960002263 vortioxetine Drugs 0.000 claims abstract description 137
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims abstract description 137
- 238000011282 treatment Methods 0.000 claims abstract description 101
- 102100034649 Zinc finger protein 551 Human genes 0.000 claims abstract description 98
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 25
- 208000028698 Cognitive impairment Diseases 0.000 claims abstract description 23
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 23
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 claims description 202
- 102000014814 CACNA1C Human genes 0.000 claims description 201
- 102100021242 Dymeclin Human genes 0.000 claims description 69
- 101000877721 Homo sapiens FOXL2 neighbor protein Proteins 0.000 claims description 68
- 102100035433 FOXL2 neighbor protein Human genes 0.000 claims description 65
- 239000000523 sample Substances 0.000 claims description 50
- 150000007523 nucleic acids Chemical class 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 44
- 108020004707 nucleic acids Proteins 0.000 claims description 44
- -1 LINC00348 Proteins 0.000 claims description 43
- 102100028284 Collagen alpha-1(XXVI) chain Human genes 0.000 claims description 36
- 101000860862 Homo sapiens Collagen alpha-1(XXVI) chain Proteins 0.000 claims description 36
- 230000002068 genetic effect Effects 0.000 claims description 29
- 238000004458 analytical method Methods 0.000 claims description 13
- 239000012472 biological sample Substances 0.000 claims description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 238000010839 reverse transcription Methods 0.000 claims description 4
- 102100040750 CUB and sushi domain-containing protein 1 Human genes 0.000 claims 50
- 101000892017 Homo sapiens CUB and sushi domain-containing protein 1 Proteins 0.000 claims 50
- 101000802315 Homo sapiens Zinc finger protein 551 Proteins 0.000 claims 32
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 claims 7
- 238000003759 clinical diagnosis Methods 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 89
- 101710143392 Zinc finger protein 551 Proteins 0.000 abstract description 68
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 208000020401 Depressive disease Diseases 0.000 abstract description 4
- 108091029795 Intergenic region Proteins 0.000 abstract description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract description 4
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 102000008186 Collagen Human genes 0.000 abstract description 3
- 108010035532 Collagen Proteins 0.000 abstract description 3
- 101150117138 FOXL2NB gene Proteins 0.000 abstract description 3
- 108090000420 L-Type Calcium Channels Proteins 0.000 abstract description 3
- 102000004016 L-Type Calcium Channels Human genes 0.000 abstract description 3
- 229920001436 collagen Polymers 0.000 abstract description 3
- 108700028369 Alleles Proteins 0.000 description 78
- 230000004044 response Effects 0.000 description 55
- 230000000694 effects Effects 0.000 description 46
- 239000000902 placebo Substances 0.000 description 37
- 229940068196 placebo Drugs 0.000 description 37
- 238000001514 detection method Methods 0.000 description 33
- 239000003153 chemical reaction reagent Substances 0.000 description 29
- 230000008859 change Effects 0.000 description 19
- 230000002349 favourable effect Effects 0.000 description 18
- 238000000926 separation method Methods 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 229960002866 duloxetine Drugs 0.000 description 12
- 210000000349 chromosome Anatomy 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000003234 polygenic effect Effects 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 101150095166 CACNA1C gene Proteins 0.000 description 5
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 230000003920 cognitive function Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000007481 next generation sequencing Methods 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- 206010012374 Depressed mood Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 208000019022 Mood disease Diseases 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 238000007844 allele-specific PCR Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940082770 vortioxetine 20 mg Drugs 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 206010011971 Decreased interest Diseases 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 101100384851 Homo sapiens COL26A1 gene Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940034706 duloxetine 60 mg Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 238000002032 lab-on-a-chip Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- VNGRUFUIHGGOOM-UHFFFAOYSA-N vortioxetine hydrobromide Chemical compound Br.CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 VNGRUFUIHGGOOM-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 101150082072 14 gene Proteins 0.000 description 1
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 1
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 101150029485 CSMD1 gene Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 101710081222 Dymeclin Proteins 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 208000036993 Frustration Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101100061535 Homo sapiens CSMD1 gene Proteins 0.000 description 1
- 101100161019 Homo sapiens ZNF551 gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100172630 Mus musculus Eri1 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 101150005878 ZSCAN4 gene Proteins 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 101150047874 dym gene Proteins 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229960004030 vortioxetine hydrobromide Drugs 0.000 description 1
- 239000006226 wash reagent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461948529P | 2014-03-05 | 2014-03-05 | |
| US61/948529 | 2014-03-05 | ||
| US201462061417P | 2014-10-08 | 2014-10-08 | |
| US62/061417 | 2014-10-08 | ||
| PCT/US2015/018701 WO2015134585A1 (en) | 2014-03-05 | 2015-03-04 | Method for treating depression and major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106536751A true CN106536751A (zh) | 2017-03-22 |
Family
ID=54055831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580023401.1A Pending CN106536751A (zh) | 2014-03-05 | 2015-03-04 | 治疗抑郁症和重性抑郁障碍的方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170137880A1 (enExample) |
| EP (1) | EP3114239A4 (enExample) |
| JP (1) | JP2017512204A (enExample) |
| KR (1) | KR20160127126A (enExample) |
| CN (1) | CN106536751A (enExample) |
| AU (1) | AU2015227296A1 (enExample) |
| CA (1) | CA2940683A1 (enExample) |
| IL (1) | IL247379A0 (enExample) |
| MA (1) | MA39485A (enExample) |
| MX (1) | MX2016011384A (enExample) |
| RU (1) | RU2016138574A (enExample) |
| WO (1) | WO2015134585A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115666624A (zh) * | 2020-05-12 | 2023-01-31 | 国际遗传工程和生物技术中心 | 作为抗癌治疗的emid2蛋白 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087735A1 (en) * | 2015-11-18 | 2017-05-26 | Millennium Pharmaceuticals, Inc. | Method for treating crohn's disease |
| PL3528811T3 (pl) * | 2017-03-30 | 2022-01-10 | Rundle Research, LLC | Wortioksetyna i inhibitory mao do leczenia depresji |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012109565A1 (en) * | 2011-02-10 | 2012-08-16 | Neurotherics, Llc | Genetic identification of response to antidepressant medications |
| WO2013074676A3 (en) * | 2011-11-14 | 2013-08-15 | The General Hospital Corporation | Assays for selecting a treatment regimen for a subject with depression and methods for treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2439201B1 (en) * | 2006-06-16 | 2013-08-07 | H. Lundbeck A/S | Compounds with combined sert, 5-ht3 and 5-ht1a activity |
| EP2581454B1 (en) * | 2008-01-17 | 2015-09-16 | Suregene LLC | Genetic markers of mental illness |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| EP2622101A4 (en) * | 2010-10-01 | 2014-04-02 | Rigshospitalet | Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors |
| US9243464B2 (en) * | 2011-02-10 | 2016-01-26 | Baker Hughes Incorporated | Flow control device and methods for using same |
-
2015
- 2015-03-04 CN CN201580023401.1A patent/CN106536751A/zh active Pending
- 2015-03-04 MX MX2016011384A patent/MX2016011384A/es unknown
- 2015-03-04 JP JP2016554883A patent/JP2017512204A/ja active Pending
- 2015-03-04 WO PCT/US2015/018701 patent/WO2015134585A1/en not_active Ceased
- 2015-03-04 EP EP15758563.9A patent/EP3114239A4/en not_active Withdrawn
- 2015-03-04 CA CA2940683A patent/CA2940683A1/en not_active Abandoned
- 2015-03-04 US US15/123,072 patent/US20170137880A1/en not_active Abandoned
- 2015-03-04 MA MA039485A patent/MA39485A/fr unknown
- 2015-03-04 RU RU2016138574A patent/RU2016138574A/ru not_active Application Discontinuation
- 2015-03-04 AU AU2015227296A patent/AU2015227296A1/en not_active Abandoned
- 2015-03-04 KR KR1020167027125A patent/KR20160127126A/ko not_active Withdrawn
-
2016
- 2016-08-21 IL IL247379A patent/IL247379A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012109565A1 (en) * | 2011-02-10 | 2012-08-16 | Neurotherics, Llc | Genetic identification of response to antidepressant medications |
| WO2013074676A3 (en) * | 2011-11-14 | 2013-08-15 | The General Hospital Corporation | Assays for selecting a treatment regimen for a subject with depression and methods for treatment |
| CN104053785A (zh) * | 2011-11-14 | 2014-09-17 | 综合医院公司 | 为患有抑郁症的受试者选择治疗方案的测定法和方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115666624A (zh) * | 2020-05-12 | 2023-01-31 | 国际遗传工程和生物技术中心 | 作为抗癌治疗的emid2蛋白 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3114239A1 (en) | 2017-01-11 |
| KR20160127126A (ko) | 2016-11-02 |
| RU2016138574A (ru) | 2018-04-06 |
| WO2015134585A1 (en) | 2015-09-11 |
| MX2016011384A (es) | 2017-05-01 |
| JP2017512204A (ja) | 2017-05-18 |
| CA2940683A1 (en) | 2015-09-11 |
| US20170137880A1 (en) | 2017-05-18 |
| RU2016138574A3 (enExample) | 2018-10-12 |
| IL247379A0 (en) | 2016-11-30 |
| AU2015227296A1 (en) | 2016-09-08 |
| MA39485A (fr) | 2015-09-11 |
| EP3114239A4 (en) | 2017-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dwivedi et al. | Diseases and molecular diagnostics: a step closer to precision medicine | |
| US20210222245A1 (en) | Autism associated genetic markers | |
| US20090197276A1 (en) | Methods and compositions for predicting compliance with an antidepressant treatment regimen | |
| Lin et al. | Gene–gene interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine kinase receptor 2 genes in geriatric depression | |
| CN106536751A (zh) | 治疗抑郁症和重性抑郁障碍的方法 | |
| CN104937113B (zh) | 用于预测由基于抗精神病药物的治疗诱导的锥体外系症状(eps)的发病的方法 | |
| US9909181B2 (en) | Biomarkers for post-traumatic stress states | |
| JP6904676B2 (ja) | カロリー制限およびカロリー制限模倣物の同定用マーカー | |
| JP2010508029A (ja) | 抗うつ薬による治療時に有害事象を発現する危険性のある患者の識別方法 | |
| CN115515680A (zh) | 用于评估神经递质转运蛋白抑制剂的功效的组合物和方法 | |
| WO2017087735A1 (en) | Method for treating crohn's disease | |
| US20190078161A1 (en) | Method for identifying clinical trial responders from a placebo group in major depression | |
| US20050255498A1 (en) | APOC1 genetic markers associated with age of onset of Alzheimer's Disease | |
| JP2007510404A (ja) | アルツハイマー病の発症年齢に関連するｎｔｒｋ１遺伝子マーカー | |
| TW201625799A (zh) | 治療憂鬱症和重度憂鬱症之方法 | |
| Amstadter et al. | Selected summaries from the XVII World Congress of Psychiatric Genetics, San Diego, California, USA, 4–8 November 2009 | |
| WO2016123543A1 (en) | Method for treating schizophrenia comprising administering lurasidone | |
| HK40083504A (en) | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | |
| Orrù et al. | Clinical Practice & Epidemiology in Mental Health | |
| Borrageiro | Investigation of differential gene expression in Parkinson's disease patients: A whole transcriptome approach | |
| Pihlstrøm | The genetics of sporadic Parkinson's disease | |
| Lefebvre et al. | Pharmacogenetics in affective disorders: a drug response approach |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170322 |